| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/13/2008 | US20080064632 Combination Therapy for the Treatment of Obesity |
| 03/13/2008 | US20080064631 T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease |
| 03/13/2008 | US20080064630 Prolonged circulation time; combined with such as human growth hormone or fragments; nucleic acid constructs, vectors, host cells; culturing and harvesting |
| 03/13/2008 | US20080064629 Promoting DNA synthesis in and preventing death of hepatocytes; regenerating parenchyma |
| 03/13/2008 | US20080064628 Injectable synthetic blood clotting compositions containing peptide bound to insoluble carrier; selectively binding activated platelets to fibrinogen; treating wounds in patients with thrombocytopenia |
| 03/13/2008 | US20080064627 Method for stimulating wound healing |
| 03/13/2008 | US20080064626 Suppressing proinflammatory response; utilizing tumor necrosis factor, nuclear factor kappa beta, interleukin and/or Interferon gamma inhibitors |
| 03/13/2008 | US20080064096 Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| 03/13/2008 | US20080064094 Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof |
| 03/13/2008 | US20080064092 Single chain polypeptide fusion comprising non-cytotoxic protease and proteinase activated receptor ligands (PAR1) domains for use in treatment and prevention of allergies, respiratory system, arthritic, skin and fibrotic disorders |
| 03/13/2008 | US20080064082 Control of function of intracellular Ca ion |
| 03/13/2008 | US20080064081 Reducing antigenicity of viral protein via amino acid sequence variation; enhancing vector transferability during gene therapy |
| 03/13/2008 | US20080064066 Modified human granulocyte-colony stimulating factor and process for producing same |
| 03/13/2008 | US20080063727 Human growth hormone, bovine, somatotropin, growth hormone releasing hormone, peptide; injection formulation dispersed in medium of buffered aqueous solution, ethanol, propyleneglycol, polyethyleneglycol, vegetable oil, mineral oil; aerosol formulation water-soluble hyaluronic acid, inorganic salt |
| 03/13/2008 | US20080063717 Anti-NCR antibody or immunoreactive fragments and an interleukin, cytokine; administered together or separately; tablet, powder, pastes, patches, granules, microgranules, nanoparticules, colloid solution, aqueous solution, injectable solutions, sprays, or liposomes; subcutaneous injection |
| 03/13/2008 | US20080063696 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant |
| 03/13/2008 | US20080063688 Biomedical devices with antimicrobial coatings |
| 03/13/2008 | US20080063674 Cosmetic Composition Containing Protein Hydrolysates |
| 03/13/2008 | US20080063661 treating a wart with a fusion protein comprising (1) a heat shock protein and (2) a human papilloma virus (HPV) protein; Mycobacterium bovis heat shock protein; HPV is an E7 protein; cervical dysplasia, anal cancer, anal dysplasia |
| 03/13/2008 | US20080063653 vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers; nucleic acid; agonist polypeptide derived from a mucin tumor antigen; genetic vaccine |
| 03/13/2008 | US20080063651 therapeutic protein comprising a tenth domain of fibronectin type III; protein scaffold; antibody design; scaffold derived from a fibronectin type III (Fn3) or Fn3-like domain, function like natural or engineered antibodies; antibody mimics designed for optimal folding, stability, and solubility |
| 03/13/2008 | US20080063643 HLA-binding motif in its sequence; recognized by an HLA-A2- or HLA-A24-restricted cytotoxic T cell; nucleotide; antibody; vector; diagnosid and prognosis of hepatitis C virus infection |
| 03/13/2008 | US20080063638 Mitotic kinesin-like protein-1, MKLP1, and uses therof priority |
| 03/13/2008 | US20080063637 Regulation of oncogenesis by Akt-specific isoforms |
| 03/13/2008 | US20080063636 polypeptides having deletions in the amino acid sequence, useful as antigens for improving vaccine therapy; treatment of Alzheimer's disease |
| 03/13/2008 | US20080063632 Recombinant host for producing l-asparaginase ii |
| 03/13/2008 | US20080063631 prophylaxis of vascular system disorders in mammals by administering apoptotic cells and/or bodies derived from leukocytes or lymphocytes |
| 03/13/2008 | US20080063626 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/13/2008 | US20080063625 Method for Managing Cholesterol with a Serum-Free and Mitogen-Free Cytokine Mixture |
| 03/13/2008 | US20080063624 administering compounds which bind to the chemokine receptors, such as 1,1'-[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, optionally with colony stimulating factors, to effect regeneration of dead myocardium |
| 03/13/2008 | US20080063623 adjuvants comprising proteins, polynucleotides, or genetic vectors and carriers |
| 03/13/2008 | US20080063600 use of deactivated lymphocytes, antibodies, drug mixtures and adjuvants, for the treatment or prevention of Cruetzfield-Jacobs disease in humans or animals; immunology; bioassays |
| 03/13/2008 | US20080060644 Method Of Treating Diabetes Mellitus In A Patient |
| 03/13/2008 | DE112004002217T5 Proteinbildungskomplex mit einem c-Jun-Protein, Nucleinsäure, codierend denselben und Verfahren unter Verwendung desselben The same protein complex formation with a c-Jun protein, nucleic acid encoding the same and methods using |
| 03/13/2008 | CA2698595A1 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| 03/13/2008 | CA2663083A1 Modified human plasma polypeptide or fc scaffolds and their uses |
| 03/13/2008 | CA2663047A1 Therapeutic elastin-like polypeptide (elp) fusion proteins |
| 03/13/2008 | CA2662716A1 Method of treating respiratory disorders |
| 03/13/2008 | CA2662715A1 Method of treating peripheral nerve disorders |
| 03/13/2008 | CA2662550A1 Potent immunostimulatory component in microalgae extract |
| 03/13/2008 | CA2662439A1 Compounds as aptamer-dimers and their uses in diagnosis and therapy |
| 03/13/2008 | CA2662041A1 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
| 03/13/2008 | CA2661839A1 Lactase-containing comestibles and related methods |
| 03/13/2008 | CA2661634A1 Selectively targeted antimicrobial peptides and the use thereof |
| 03/13/2008 | CA2661308A1 Neukinase, a downstream protein of neuregulin |
| 03/13/2008 | CA2656227A1 Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient |
| 03/13/2008 | CA2654283A1 Methods of diagnosing and treating complications of pregnancy |
| 03/13/2008 | CA2559634A1 Pharmaceutical preparations for the treatment of arthritis |
| 03/12/2008 | EP1897950A2 Human GIL-19/AE289 proteins and polynucleotides encoding same |
| 03/12/2008 | EP1897949A2 Human interleukin-B50. Therapeutic uses |
| 03/12/2008 | EP1897948A1 Mammalian transforming growth factor beta 9 |
| 03/12/2008 | EP1897947A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897946A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897945A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897944A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897943A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897942A1 Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| 03/12/2008 | EP1897889A2 Method of modulating the profileration of medullary thyroid carcinoma cells |
| 03/12/2008 | EP1897888A1 Peptides binding the TPO receptor |
| 03/12/2008 | EP1897886A1 Compounds as aptamer-dimers and their uses in diagnosis and therapy |
| 03/12/2008 | EP1897561A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 03/12/2008 | EP1897556A1 Prevention and treatment of hypergastrinemia |
| 03/12/2008 | EP1897554A1 Method for the manufacture of a medicament for treating hemorrhagic stroke |
| 03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
| 03/12/2008 | EP1897552A1 Polymer-conjugated glycosylated neublastin |
| 03/12/2008 | EP1897551A1 Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage |
| 03/12/2008 | EP1897550A2 Prodrugs of Excitatory Amino Acids |
| 03/12/2008 | EP1897546A1 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| 03/12/2008 | EP1897541A2 Hypoglycemic agent |
| 03/12/2008 | EP1897540A2 Inhibition of STAT3 signal transduction for human cancer therapy |
| 03/12/2008 | EP1897441A1 TGF-alpha polypeptides, functional fragments and methods of use therefor |
| 03/12/2008 | EP1896605A2 Stimulation of pancreatic b cell proliferation |
| 03/12/2008 | EP1896588A1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF |
| 03/12/2008 | EP1896579A2 Cytotoxic ribonuclease variants |
| 03/12/2008 | EP1896577A2 Lipases for pharmaceutical use |
| 03/12/2008 | EP1896502A1 Treatment of fungal and/or protist infections |
| 03/12/2008 | EP1896500A2 Gliomedin, fragments thereof and methods of using same |
| 03/12/2008 | EP1896499A2 Hecgf-1 related polymorphisms and applications thereof |
| 03/12/2008 | EP1896386A1 Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| 03/12/2008 | EP1896134A2 Methods and compositions for treating degenerative bone disorders |
| 03/12/2008 | EP1896081A1 Human granulocyte-colony stimulating factor isoforms |
| 03/12/2008 | EP1896080A2 Toxin peptides with extended blood halflife |
| 03/12/2008 | EP1896072A2 A direct drug delivery system based on thermally responsive biopolymers |
| 03/12/2008 | EP1896071A2 Methods and compositions with enhanced therapeutic activity |
| 03/12/2008 | EP1896059A2 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract |
| 03/12/2008 | EP1896058A2 Proteases for pharmaceutical use |
| 03/12/2008 | EP1896057A2 Amylases for pharmaceutical use |
| 03/12/2008 | EP1896056A1 Reinforced collagen scaffold |
| 03/12/2008 | EP1896055A1 Immune disease medicament comprising a modulator of the binding between a heparin binding domain of thrombospondin-1 and a beta1 integrin |
| 03/12/2008 | EP1896054A1 Stable buffered, pharmaceutical compositions including motilin-like peptides |
| 03/12/2008 | EP1896053A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 03/12/2008 | EP1896052A1 Methods and compositions for enhancing developmental potential of oocytes and preimplantation embryos |
| 03/12/2008 | EP1896051A2 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine |
| 03/12/2008 | EP1896050A2 Lkktet and/or lkktnt peptide compositions and methods |
| 03/12/2008 | EP1896049A1 Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1 |
| 03/12/2008 | EP1896048A2 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 03/12/2008 | EP1896047A1 Anti-gfralpha3 antibodies |
| 03/12/2008 | EP1896046A2 Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1) |
| 03/12/2008 | EP1895989A2 A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
| 03/12/2008 | EP1789440A4 Pancreatic polypeptide family motifs and polypeptides comprising the same |